Abstracts tagged "Drug toxicity"

Abstract Number: 0712 • ACR Convergence 2021
Immune Checkpoint Inhibitor-related Myotoxicity : Musculoskeletal and/or Neuromuscular Junction Disorder ?
Hortense Chassepot¹, Lotta Plomp², Dimitri Psimaras³, Thierry Maisonobe³, Sarah Leonard Louis⁴, Isabelle Plu⁴, Mehdi Touat³, Celine Anquetil⁵, Nadege Wesner⁵, Nicolas Champtiaux⁵, Aude Rigolet⁵, Sophie Demeret³, Nicolas Weiss³, Baptiste Abbar⁶, Marie-Claire Bretagne⁷, Bruno Pinna⁷, Capucine Morelot⁸, Martin Dres⁸, Thomas Similowski⁸, Stephane Ederhy⁹, Joe-Elie Salem⁷, Olivier Benveniste⁵ and Yves Allenbach⁵, ¹Universite de Picardie Jules Verne UPJV - Amiens Picardie Hospital, Department of Clinical Immunology and Internal Medicine, Fourqueux, France, ²Amsterdam University Medical Center (AUMC), Amsterdam, Netherlands, ³Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Neurology, Paris, France, ⁴Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Neuropathology, Paris, France, ⁵Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, Paris, France, ⁶Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Oncology, Paris, France, ⁷Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, Paris, France, ⁸Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Pneumology - R3S, Paris, France, ⁹Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Cardiology, Paris, France
Background/Purpose: Immune checkpoint inhibitor (ICI)-related adverse events (irAE) recently emerged as new diseases in the field of auto-immunity. Among them, ICI-related myotoxicity has the highest…
Abstract Number: 0753 • ACR Convergence 2021
Patient-Reported Burden of Adverse Drug Reactions Attributed to the Use of Adalimumab and Etanercept in Patients with Inflammatory Rheumatic Diseases
John Davelaar¹, Naomi Jessurun², Sander Tas³, Mike Nurmohamed⁴, Bart van den Bemt⁵ and Harald Vonkeman⁶, ¹Netherlands Pharmacovigilance Centre Lareb, Utrecht, Netherlands, ²Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, Netherlands, ³Amsterdam UMC, locatie AMC, Utrecht, Netherlands, ⁴Reade; Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, ⁵Sint Maartenskliniek; Radboud University Medical Center, Ubbergen, Netherlands, ⁶Medisch Spectrum Twente; University of Twente, Enschede, Netherlands
Background/Purpose: Health care professionals tend to focus on adverse drug reactions (ADRs) with the highest clinical impact. Subsequently, ADRs with less obvious clinical impact but…
Abstract Number: L08 • ACR Convergence 2020
Long Term Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Chronic Gout: The Febuxostat versus Allopurinol Streamlined Trial (on Behalf of the FAST Investigators)
Thomas MacDonald¹, Isla Mackenzie¹, George Nuki² and Ian Ford³, ¹University of Dundee, Dundee, Scotland, United Kingdom, ²University of Edinburgh, Edinburgh, Scotland, United Kingdom, ³University of Glasgow, Glasgow, Scotland, United Kingdom
Background/Purpose: Febuxostat and allopurinol are uric acid lowering agents. Following concerns about the cardiovascular safety of febuxostat, the European Medicines Agency (EMA) recommended a post-authorization…
Abstract Number: 0223 • ACR Convergence 2020
Safety of Low Dose Methotrexate (MTX) and Tuberculosis (TB)
Anna Davidson¹, Alize Gunay¹, Ines Colmegna², Diane Lacaille³, Harold Loewen⁴, Michele Meltzer⁵, Yewondwossen Tadese⁶, Zenebe Yirsaw⁶, Sasha Bernatsky⁷ and Carol Hitchon⁴, ¹McGill University, Montreal, QC, Canada, ²The Research Institute of the McGill University Health Centre, Montreal, Canada, ³University of British Columbia / Arthritis Research Canada, Richmond, BC, Canada, ⁴University of Manitoba, Winnipeg, MB, Canada, ⁵Jefferson University, Philadelphia, PA, ⁶Addis Ababa University, Addis Ababa, Adis Abeba, Ethiopia, ⁷The Research Institute of the McGill University Health Centre, Montreal, ON, Canada
Background/Purpose: Increased awareness of the importance of MTX in rheumatic disease is leading to more MTX use in patients from TB-endemic areas. Current management guidelines…
Abstract Number: 1635 • ACR Convergence 2020
Profile of Topical Diclofenac Sodium Gel 1% (Voltaren®) Users in a United States Longitudinal Electronic Health Records Database
Amy Kenneally¹, Frédérique Bariguian², Richard Petruschke¹, Arlene Tave³, Jess Edison⁴, Nicholas M. Sicignano⁵ and Francis Barbone¹, ¹GSK Consumer Healthcare, Warren, NJ, ²GSK Consumer Healthcare S.A., Nyon, Switzerland, ³PharmaLex US Corporation, Fairfax, VA, ⁴Walter Reed National Military Medical Center, Bethesda, ⁵Health ResearchTx LLC., Prevose, PA
Background/Purpose: Diclofenac sodium gel 1% (DSG), a topical non-steroidal anti-inflammatory drug (NSAID), is effective for the relief of osteoarthritis (OA) pain in the elbows, wrists,…
Abstract Number: 0431 • ACR Convergence 2020
Hydroxychloroquine Use Was Not Associated with QTc Length in a Large Cohort of SLE and RA Patients
Elizabeth Park¹, Jon Giles², Thania Perez-Recio¹, Paloma Pina³, Christopher Depender¹, Joan Bathon¹ and Laura Geraldino-Pardilla⁴, ¹Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, ²Columbia University, New York, NY, ³Cardiac Electrophysiology, Northwestern Medicine, Chicago, IL, ⁴Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York
Background/Purpose: Hydroxychloroquine (HCQ) is a cornerstone therapy for systemic lupus erythematosus (SLE), and is used as monotherapy and combined with other DMARDs in rheumatoid arthritis…
Abstract Number: 1779 • ACR Convergence 2020
Gap in Contraceptive Education to Females with Rheumatic Disease on Teratogenic Medications
Andras Perl¹, Sundus Mian¹ and Jihad Ben Gabr¹, ¹SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Teratogenic disease-modifying anti-rheumatic disease modifying drugs (DMARDs) are often prescribed to women of childbearing age. Contraception represents an important area of reproductive health for female patients with…
Abstract Number: 0540 • ACR Convergence 2020
Risk of Hydroxychloroquine Retinopathy in the Community
Jesse Dabit¹, Mehmet Hocaoglu², Kevin Moder¹, Andrew Barkmeier³, Wendy Smith³, Thomas O'Byrne¹, Cynthia Crowson⁴ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²University of Maryland Medical Center Midtown Campus, Baltimore, MD, ³Mayo Clinic, Rochester, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: Hydroxychloroquine (HCQ) is used in the treatment of a wide variety of autoimmune diseases. HCQ retinopathy is a feared complication of long-term use. The…
Abstract Number: 1825 • ACR Convergence 2020
Risk Factors for Antimalarial-Induced Retinal Toxicity in Systemic Lupus Erythematosus and Other Rheumatic Diseases
Gemma Cramarossa¹, Hsin-Yen Liu² and Janet Pope³, ¹Western University, Kleinburg, ON, Canada, ²Western University, London, ON, Canada, ³Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada
Background/Purpose: Hydroxychloroquine (HCQ) and chloroquine (CQ) are antimalarial (AM) medications prescribed for a variety of rheumatic diseases, including systemic lupus erythematosus (SLE). Many patients will…
Abstract Number: 0588 • ACR Convergence 2020
Feast or Famine? An Institutional Assessment of Hydroxychloroquine Screening Practices
Alanna James¹, Kelli Kam¹, Vaneet Sandhu² and Christina Downey³, ¹Loma Linda University Health, Loma Linda, CA, ²Loma Linda University, Loma Linda, CA, ³Loma Linda University Medical Center, Redlands, CA
Background/Purpose: Hydroxychloroquine (HCQ) is a generally safe and widely used rheumatologic drug. Maculopathy is an adverse effect in < 1% in the first 5 years…
Abstract Number: 1830 • ACR Convergence 2020
Adverse Drug Reactions to Trimethoprim-sulfamethoxazole as a Prophylactic Agent Against Pneumocystis Pneumonia in Patients with Systemic Lupus Erythematosus: anti-Sm Antibody as a Possible Risk Factor
Shinji Izuka¹, Hiroyuki Yamashita², Yuko Takahashi² and Hiroshi Kaneko², ¹Devision of Rheumatic Disease, National Center for Global Health and Medicine, Toshima-Ku, Tokyo, Japan, ²Devision of Rheumatic Disease, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan
Background/Purpose: Pneumocystis pneumonia (PCP) is a life-threatening infection in immunocompromised patients, including those with connective tissue diseases (CTDs), treated with corticosteroids or immunosuppressive agents. Trimethoprim-sulfamethoxazole…
Abstract Number: 0952 • ACR Convergence 2020
Reducing Immunogenicity of Pegloticase (RECIPE) with Concomitant Use of Mycophenolate Mofetil in Patients with Refractory Gout—a Phase II Double Blind Randomized Controlled Trial
Puja Khanna¹, Dinesh Khanna¹, Gary Cutter², Jeffrey Foster², Joshua Melnick³, Sara Jaafar¹, Stephanie Biggers², AKM Rahman², Hui-Chen Kuo², Michelle Feese² and Kenneth Saag⁴, ¹University of Michigan, Ann Arbor, MI, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham (UAB), Vestavia Hills, AL, ⁴University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL
Background/Purpose: Pegloticase, a recombinant, pegylated uricase, is used for treatment of gout in patients who fail oral urate lowering therapy (ULT). Despite successful reduction of…
Abstract Number: 1844 • ACR Convergence 2020
Hydroxychloroquine and QTc Prolongation in a Cohort of SLE Patients
Mayce Haj-Ali¹ and H. Michael Belmont², ¹NYU Langone Health, new york, ²NYU School of Medicine, New York, NY
Background/Purpose: Hydroxychloroquine (HCQ) is an antimalarial drug used in the treatment of systemic lupus erythematous (SLE). Cardiac toxicity is very rare in SLE, but has…
Abstract Number: 1015 • ACR Convergence 2020
The Prevalence and Risk Factors for Liver Fibrosis Among Rheumatoid Arthritis (RA) Patients on Disease-Modifying Anti-rheumatic Drugs (DMARDs)
Chou Luan Tan¹, Boon Han Ng², Noor Shahrazat Ahmad², Shahrul Aiman Soelar², Muhammad Zulhilmi Asyraf Jazlan², Mohd Ammar Dzakirin Md Mansor², Mohd Azri Mohd Suan², Kuang Kiat Kiew², Zalwani Zainuddin², Muhammad Radzi Abu Hassan² and Chong Hong Lim², ¹Hospital Sultanah Bahiyah, Kementerian Kesihatan Malaysia, Alor Setar, Kedah, Malaysia, ²Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia
Background/Purpose: Majority of DMARDs, including methotrexate (MTX), leflunomide (LEF) and sulfasalazine (SSZ) arebelieved to be hepatotoxic, causing liver fibrosis. However, the clinical findings were inconsistent.…
Abstract Number: 1846 • ACR Convergence 2020
Evaluating the Risk of QT-prolongation Associated with Hydroxychloroquine Use with and Without Antidepressants in SLE Patients with Fibromyalgia
Jacinta Renaldi¹, Fotios Koumpouras¹ and Mei Xue Dong¹, ¹YALE SCHOOL OF MEDICINE, New Haven, CT
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex systemic autoimmune disease predominantly affecting woman of child-bearing age. Concurrent fibromyalgia syndrome (FMS) has been reported in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].